Cooper Companies (COO)
NASDAQ:COO
Top Page
Cooper Co
(NASDAQ:COO)
Select Model
Select Model
Rating:64Neutral
Price Target:
$75.00
▲(4.60% Upside)
Action:ReiteratedDate:04/09/26
The score is driven by solid financial health and a positive earnings-call catalyst (raised EPS/FCF guidance and continued capital returns), partially offset by weak technicals (downtrend and negative momentum) and a relatively high P/E with no dividend support.
Positive Factors
Sustained market share gains & product momentum
Long-term share gains and strong adoption of premium SKUs (MyDay multifocal, Energys, torics) plus rapid MiSight myopia growth indicate durable product leadership. Consistent outperformance versus market suggests entrenched distribution, brand strength, and structural demand for differentiated contact lenses.
Negative Factors
Asia Pacific / Japan softness
Recurring weakness in Japan and lower-margin legacy hydrogel demand can depress organic growth and mix over multiple quarters. Given the region's size, prolonged underperformance or slower recovery would constrain consolidated organic growth and require sustained marketing or pricing investments to restore trend.
Read all positive and negative factors
Positive Factors
Negative Factors
Sustained market share gains & product momentum
Long-term share gains and strong adoption of premium SKUs (MyDay multifocal, Energys, torics) plus rapid MiSight myopia growth indicate durable product leadership. Consistent outperformance versus market suggests entrenched distribution, brand strength, and structural demand for differentiated contact lenses.
Read all positive factors
Cooper Co (COO) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$13.89B
Dividend YieldN/A
Average Volume (3M)2.09M
Price to Earnings (P/E)30.6
Beta (1Y)0.73
Revenue Growth5.06%
EPS Growth-4.47%
CountryUS
Employees16,000
SectorHealthcare
Sector Strength45
IndustryMedical - Instruments & Supplies
Share Statistics
EPS (TTM)1.10
Shares Outstanding195,114,400
10 Day Avg. Volume1,748,403
30 Day Avg. Volume2,094,064
Financial Highlights & Ratios
PEG Ratio-8.16
Price to Book (P/B)1.70
Price to Sales (P/S)3.42
P/FCF Ratio32.24
Enterprise Value/Market Cap1.18
Enterprise Value/Revenue3.94
Enterprise Value/Gross Profit6.13
Enterprise Value/Ebitda16.99
Forecast
1Y Price Target
$91.70Price Target Upside27.89% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering11
EPS Forecast (FY)4.62
Revenue Forecast (FY)$4.32B
Cooper Co Business Overview & Revenue Model
Company Description
The Cooper Companies, Inc., together with its subsidiaries, develops, manufactures, and markets contact lens wearers. The company operates in two segments, CooperVision and CooperSurgical. The CooperVision segment offers spherical lense, including...
How the Company Makes Money
Cooper Co. generates revenue primarily by designing, manufacturing, and selling advanced medical products through its two main operating segments. CooperVision drives income by offering a broad portfolio of contact lenses, catering to various visi...
Cooper Co Key Performance Indicators (KPIs)
Any
Revenue by Geography
Breaks down revenue across different regions, revealing where the company is strongest and where it may face risk or growth potential due to local economic conditions or market share shifts.
Breaks down revenue across different regions, revealing where the company is strongest and where it may face risk or growth potential due to local economic conditions or market share shifts.
Data provided by:
The Fly
The FlyCooper Co Earnings Call Summary
Earnings Call Date:Mar 05, 2026
(Q1-2026)
| % Change Since: |
Next Earnings Date:May 28, 2026
Earnings Call Sentiment Positive
The call emphasized strong operational execution with revenue growth, a substantial EPS beat (+20%), robust free cash flow and raised guidance for earnings and FCF. Product momentum (MyDay and MiSight), continued market share gains, and realized synergies from reorganization and AI/IT investments are clear positives. Key challenges include Asia Pacific (notably Japan) softness that modestly depressed quarterly organic growth, some regional fertility and Paragard pressures, tariff/FX headwinds and isolated legal costs. Management expects these headwinds to be temporary (APAC recovery in Q3) and is allocating savings to growth initiatives while continuing buybacks and debt reduction.Positive Updates
Consolidated Revenue Growth
Consolidated revenue of $1.024 billion, up 6.2% year-over-year (organic growth +2.9%).
Negative Updates
Asia Pacific Weakness — Japan Pressure
Asia Pac revenue declined 4% (dragged by softness in Japan driven by lower-margin legacy hydrogel products). Management expects Asia Pac to remain down in Q2 before returning to growth in fiscal Q3.
Read all updates
Q1-2026 Updates
Positive
Negative
Consolidated Revenue Growth
Consolidated revenue of $1.024 billion, up 6.2% year-over-year (organic growth +2.9%).
Read all positive updates
Company Guidance
Cooper raised full-year financial expectations after a Q1 beat, keeping consolidated revenue guidance essentially unchanged at roughly $4.30–$4.35 billion (organic growth ~4.5%–5.5%) while raising non‑GAAP EPS to $4.58–$4.66; segment targets call for CooperVision revenue of $2.90–$2.93 billion (organic +4.5%–5.5%) and CooperSurgical $1.40–$1.41 billion (organic +4%–5%). Management reiterated a tariff assumption of about $24 million, expects interest expense around $85 million and an effective tax rate of 15%–16%, and raised fiscal‑2026 free cash flow guidance to $600–$625 million (with fiscal 2026–2028 free cash flow expected to exceed $2.2 billion). The guidance lift follows a strong Q1 that delivered $1.024 billion revenue (+6.2% / +2.9% organic), CooperVision $695 million (+7.6% / +3.3% organic), CooperSurgical $329 million (+3.3% / +2.2% organic), non‑GAAP EPS of $1.10 (+20%), $159 million free cash flow (CapEx $102 million), $92 million of buybacks (1.1M shares), ~197 million shares outstanding and net debt of $2.4 billion.Cooper Co Financial Statement Overview
Summary
Income Statement
72
Positive
Balance Sheet
78
Positive
Cash Flow
69
Positive
| Breakdown | TTM | Oct 2025 | Oct 2024 | Oct 2023 | Oct 2022 | Oct 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 4.15B | 4.09B | 3.90B | 3.59B | 3.31B | 2.92B |
| Gross Profit | 2.67B | 2.48B | 2.60B | 2.36B | 2.14B | 1.96B |
| EBITDA | 962.00M | 1.05B | 1.07B | 885.90M | 878.70M | 823.90M |
| Net Income | 401.40M | 374.90M | 392.30M | 294.20M | 385.80M | 2.94B |
Balance Sheet | ||||||
| Total Assets | 12.42B | 12.39B | 12.32B | 11.66B | 11.49B | 9.61B |
| Cash, Cash Equivalents and Short-Term Investments | 124.90M | 110.60M | 107.60M | 120.90M | 138.20M | 95.90M |
| Total Debt | 2.50B | 2.78B | 2.58B | 2.57B | 2.76B | 1.48B |
| Total Liabilities | 4.06B | 4.16B | 4.23B | 4.11B | 4.32B | 2.66B |
| Stockholders Equity | 8.36B | 8.24B | 8.08B | 7.55B | 7.17B | 6.94B |
Cash Flow | ||||||
| Free Cash Flow | 491.20M | 433.70M | 288.10M | 215.00M | 450.40M | 524.20M |
| Operating Cash Flow | 866.40M | 796.10M | 709.30M | 607.50M | 692.40M | 738.60M |
| Investing Cash Flow | -379.00M | -372.90M | -764.60M | -449.00M | -1.83B | -450.30M |
| Financing Cash Flow | -477.20M | -425.90M | 39.20M | -173.90M | 1.19B | -311.40M |
Cooper Co Technical Analysis
Neutral
71.70
Price Trends
76.69
Negative
78.44
Negative
74.65
Negative
Market Momentum
-1.45
Negative
45.12
Neutral
74.71
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For COO, the sentiment is Neutral. The current price of 71.7 is above the 20-day moving average (MA) of 70.84, below the 50-day MA of 76.69, and below the 200-day MA of 74.65, indicating a neutral trend. The MACD of -1.45 indicates Negative momentum. The RSI at 45.12 is Neutral, neither overbought nor oversold. The STOCH value of 74.71 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for COO.
Cooper Co Risk Analysis
Cooper Co disclosed 40 risk factors in its most recent earnings report. Cooper Co reported the most risks in the "Legal & Regulatory" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Cooper Co Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
72 Outperform | $18.48B | 40.29 | 16.68% | 0.32% | 4.90% | -0.26% | |
65 Neutral | $8.47B | 20.41 | 14.68% | 1.50% | 2.50% | 25.05% | |
64 Neutral | $13.89B | 30.60 | 4.83% | ― | 5.06% | -4.47% | |
64 Neutral | $9.31B | -45.07 | -17.21% | ― | -16.03% | -813.48% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
46 Neutral | $8.85B | -10.24 | -13.78% | 2.75% | -21.20% | -325.40% |
* Healthcare Sector Average
COO
Cooper Co
71.70
-6.10
-7.84%
ATR
AptarGroup
132.11
-9.92
-6.99%
BAX
Baxter International
17.63
-9.80
-35.72%
MASI
Masimo
178.47
26.41
17.37%
WST
West Pharmaceutical Services
259.96
48.21
22.77%
Cooper Co Corporate Events
Executive/Board ChangesShareholder Meetings
Cooper Co Stockholders Approve Directors, Auditor and Pay
Positive
Apr 8, 2026
On April 7, 2026, The Cooper Companies, Inc. held its 2026 Annual Meeting of Stockholders, at which stockholders elected nine directors, including Colleen E. Jay, Barbara A. Carbone, and Albert G. White III, to serve until the 2027 annual meeting ...
Business Operations and StrategyPrivate Placements and Financing
Cooper Co Amends Loan Facilities to Enhance Flexibility
Positive
Feb 4, 2026
On February 3, 2026, The Cooper Companies, Inc. amended its 2021 Term Loan Agreement by extending the maturity date of $950 million of its term loans to February 3, 2031 while leaving the $550 million balance unchanged, removing the credit spread ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.